Horizon 2020 Project ValueCare: Value-based methodology for integrated care supported by Information and Communication Technology
| ISRCTN | ISRCTN25089186 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN25089186 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | Horizon 2020 Grant Agreement number 875215 |
| Sponsor | Erasmus MC |
| Funder | Horizon 2020 Framework Programme |
- Submission date
- 15/09/2021
- Registration date
- 16/11/2021
- Last edited
- 27/01/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Other
Plain English summary of protocol
Background and study aims
The Information and Communication Technology (ICT) enabled value-based methodology for integrated care (ValueCare) approach aims to deliver efficient outcome-based, integrated health and social care to older persons with multimorbidity, mild to moderate cognitive impairment, and frailty. In comparison with ‘usual care’, the ValueCare approach is expected to achieve more favourable outcomes for older persons (65 years and older), their informal caregivers, and health and social care practitioners. This study aims to examine the effectiveness and implementation of ValueCare in seven large-scale pilots in Europe including Athens, Greece; Coimbra, Portugal; Cork/Kerry, Ireland; Rijeka, Croatia; Rotterdam, the Netherlands; Treviso, Italy, and; Valencia, Spain.
Who can participate?
Older persons (aged 65 years and older), their informal caregivers, and health and social care practitioners based in the participating areas.
What does the study involve?
Each pilot site will design an integrated care pathway based on the ValueCare model for the target population. The assessment and personalized care plan will be enhanced by a mobile health application (i.e., the ValueCare app) for older persons. If the patient provides consent, informal caregivers and health and social care practitioners can have access to a web-based application (i.e., the ValueCare web application) that monitors the progress of the patient.
Data will be collected in pilot sites at inclusion (before ValueCare), after 12 months, and after 18 months to assess the benefits of the ValueCare approach versus usual care. Information on indicators of health, wellbeing, and quality of life; lifestyle behaviour; health care use; perceived carer burden; and (job) satisfaction will be collected. In addition, the acceptability, appropriateness, feasibility, fidelity and costs of the ValueCare approach will be measured.
What are the possible benefits and risks of participating?
Benefits
By participating in this study, patients are contributing to the development of the future health care provided to older persons.
Risks
As this is a non-invasive study, no significant risks for participants are foreseen. However, if a certain risk occurs in a pilot site, there is a related policy available, including guidance on ethical procedures how to deal with them, as they arise.
Where is the study run from?
Erasmus MC (The Netherlands)
When is the study starting and how long is it expected to run for?
From April 2021 to April 2024
Who is funding the study?
The European Commission, Horizon 2020 call Digital Transformation in Health and Care
Who is the main contact?
Prof Hein Raat
h.raat@erasmusmc.nl
Contact information
Public
Wytemaweg 80
Rotterdam
3000 CA
Netherlands
| 0000-0002-6000-7445 | |
| Phone | +31107038580 |
| h.raat@erasmusmc.nl |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Multicenter specific pre-post controlled non-randomized study design |
| Secondary study design | Non randomised study |
| Study type | Participant information sheet |
| Scientific title | ‘Value-based methodology for person-centred, integrated care supported by Information and Communication Technologies’ (ValueCare): a preventive integrated health and social care approach for older persons’ care in seven European countries |
| Study acronym | ValueCare |
| Study objectives | Older persons in the intervention group (i.e. individuals receiving ValueCare) will have more favourable results with regard to indicators of health, wellbeing, and quality of life; lifestyle behavior; and reduced health care use compared with older persons participating in the comparison group (i.e. individuals receiving ‘usual care’). With respect to the informal caregivers and health and social care practitioners, lower caregiver burden, and improved wellbeing and (job) satisfaction among participants in the intervention group are expected. Furthermore, it is expected that the costs of care for the intervention group will be lower, compared to the comparison group. |
| Ethics approval(s) |
1. Approved 26/11/2021, Medische Ethische Commissie (MEC) – Erasmus Medical Center Rotterdam (Erasmus MC, Room Ae-337, Dr. Molewaterplein 40, Rotterdam, 3015 GD, Netherlands; +31 (0)10-70 34428, +31 (0)10-70 33625; metc@erasmusmc.nl), ref: 20210727 2. Approved 18/04/2022, Ethics and Conduct committee (Athens Medical Center, Athens, 15125, Greece; +30 2106198100; info@iatriko.gr), ref: Ε.Σ. 86/ 12-04-22 3. Approved 24/03/2022, Comissão da Administração Regional de Saúde do Centro (no address provided, Coimbra, no zip code provided, Portugal; no telephone number provided; noemail@provided), ref: 13-2022 4. Approved 11/08/2021, University College Dublin Human Research Ethics Committee (UCD HREC) and Clinical Research Ethics Commit tee of the Cork Teaching Hospital (CREC) (no address provided, Cork, no zip code provided, Ireland; no telephone number provided; noemail@provided), ref: LS-21-69-Darley 5. Approved 31/08/2021, The Ethical Committee—Faculty of Medicine, University of Rijeka (no address provided, Rijeka, no zip code provided, Croatia; no telephone number provided; noemail@provided), ref: 2170-24-04-3-21-11 6. Approved 03/03/2022, Comitato Etico per Sperimentazione Clinica delle province di Treviso e Belluno (no address provided, Treviso, no zip code provided, Italy; no telephone number provided; noemail@provided), ref: 1159/CE Marca 7. Approved 07/05/2020, Comisión de Ética en Investigación Experimental de la Universitat de València (no address provided, Valencia, no zip code provided, Spain; no telephone number provided; noemail@provided), ref: no ref provided |
| Health condition(s) or problem(s) studied | Older persons living with medical conditions, disabilities, frailty, and/or mild to moderate cognitive decline |
| Intervention | In the intervention condition, the ValueCare approach will be applied. In the control condition ‘usual care’ is applied. Each pilot site will design an integrated care pathway based on the ValueCare model for the target population. In all pilots the value-based care approach is applied, which is a specific application of ‘outcome-based care delivery’ developed by the International Consortium for Health Outcomes Measurements (ICHOM: www.ichom.org). This entails that a self-reported questionnaire will be administered to assess the physical, mental, and overall well-being of the participants. The aim of this assessment is to identify the individual care needs of older persons, and to monitor and discuss the outcomes with the patient and their caregiver. Based on the assessment’s outcomes and detected needs, each patient will be given a personalized care plan which is co-produced by the patient, their caregiver, and care team members. The shared care plan will be periodically reviewed and can be adjusted in line with people’s health and wellbeing. The stakeholders involved in the ValueCare pathway, including patients and care providers, are supported by the ValueCare technical solution. The assessment and personalized care plan will be enhanced by a mobile health application (i.e., the ValueCare app) for older persons. If the patient provides consent, informal caregivers and care team members can have access to a web-based application (i.e., the ValueCare web application) that monitors the progress of the patient. Data will be collected at baseline (T0), after 12 months (T1), and after 18 months (T2) by using self-reported questionnaires. |
| Intervention type | Not Specified |
| Primary outcome measure(s) |
Health-related quality of life (HR-QoL) score measured using the PROMIS Scale v1.2 – Global Health (PROMIS-10) at baseline, 12, and 18 months |
| Key secondary outcome measure(s) |
1. Loneliness measured using the UCLA 3-Item Loneliness Scale (Hughes et al., 2004) at baseline, 12, and 18 months |
| Completion date | 30/04/2024 |
Eligibility
| Participant type(s) | |
|---|---|
| Age group | Mixed |
| Sex | All |
| Target sample size at registration | 1680 |
| Key inclusion criteria | 1. Older persons: 1.1. Aged ≥65 years 1.2. Have a confirmed diagnosis of the targeted chronic condition at the time of enrolment 1.3. Community-dwelling (not living in long-term care facilities) or are temporarily in a hospital or institution and are expected to be referred to outpatient rehabilitation services 1.4. Able to give informed consent 2. Informal and formal caregivers: 2.1. Informal caregivers (e.g., relatives, friends) of participating older persons will be approached to participate in the study 2.2. Health and social care practitioners who work with older persons having the targeted condition in each pilot site will be approached to participate in the study |
| Key exclusion criteria | Unable to comprehend the information provided in the local language or cannot cognitively evaluate the risks and benefits of participation |
| Date of first enrolment | 01/11/2021 |
| Date of final enrolment | 31/07/2023 |
Locations
Countries of recruitment
- Croatia
- Greece
- Ireland
- Italy
- Netherlands
- Portugal
- Spain
Study participating centres
Rotterdam
3015 GD
Netherlands
Marousi
Athens
15125
Greece
Valencia
46024
Spain
Treviso
31100
Italy
Rijeka
51000
Croatia
Coimbra
3030-382
Portugal
Dublin 2
0000
Ireland
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Protocol article | in Valencia (Spain) | 31/05/2024 | 28/06/2024 | Yes | No |
| Protocol article | in Rijeka (Croatia) | 03/01/2025 | 27/01/2025 | Yes | No |
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
| Study website | Study website | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
27/01/2025: Publication reference added.
28/06/2024: Publication reference added.
17/11/2023: The following changes were made to the trial record:
1. The overall end date was changed from 30/11/2023 to 30/04/2024.
2. The intention to publish date was changed from 01/11/2024 to 31/03/2025.
3. The plain English summary was updated to reflect these changes.
26/10/2023: The ethics approvals were added (1-7).
23/10/2023: The following changes have been made:
1. Ethics approval for Greece added.
2. The recruitment end date was changed from 30/06/2022 to 31/07/2023.
11/10/2021: Trial’s existence confirmed by the European Commission.